drugset / Trial / NCT01508949

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NCT01508949

Phase 2 Completed 35 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Timeline

Start
2001-06
Primary completion
2002-03
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 0.6 mg Subcutaneous